The antitumor cytotoxic T cell activity of T-αFGL2 cells against the FGL2-expressing murine glioma cell line, DBT, was evaluated by measuring the proportion of live glioma cells and granzyme B+, interferon γ (IFNγ)+, and tumor necrosis factor α (TNFα)+ T cells (Fig. 1d). This evidence concerns the gene TNF and central nervous system cancer.